DEA Marijuana Rescheduling Timeline Faces New Uncertainty as 2026 Deadline Looms

Administrative Law Judge Hearings Still Pending

The DEA hasn't yet scheduled the mandatory administrative law judge (ALJ) hearings required under 21 U.S.C. § 811(a) for controlled substance rescheduling. The agency published its NPRM in May 2024, triggering a 60-day public comment period that closed in July 2024. More than 43,000 comments poured into docket DEA-407. That's the largest response in DEA rescheduling history.

Under the Administrative Procedure Act, the DEA must review all substantive comments and respond to them in its final rule. It must also convene ALJ hearings if any party with standing requests one—a threshold multiple industry groups and state attorneys general have met. No hearing dates have been announced.

Political and Procedural Variables Complicate Timeline

The rescheduling process depends on coordination between the DEA, the Department of Health and Human Services (HHS), and the White House Office of Management and Budget (OMB). HHS completed its scientific review in August 2023, recommending Schedule III placement based on marijuana's accepted medical use and lower abuse potential relative to Schedule I and II substances.

Final authority under the CSA rests with the DEA. The agency's current timeline depends on how quickly it can process the comment record, schedule ALJ hearings, and draft a final rule that survives OMB regulatory review—each step historically takes months, and the DEA hasn't published an updated timeline since May 2024.

Industry Operators Hedge on Tax and Banking Relief

Cannabis operators have banked on rescheduling to eliminate Internal Revenue Code Section 280E, which prohibits state-legal cannabis businesses from deducting ordinary business expenses. Schedule III placement would end 280E's application to cannabis. That could save multi-state operators tens of millions annually.

But the timeline slippage is forcing operators to plan for a scenario in which 280E remains in effect through 2027. Several MSOs disclosed in recent earnings calls that they aren't modeling 280E relief into 2026 guidance. Banking access—another hoped-for benefit of rescheduling—also remains uncertain, as Schedule III substances still face restrictions under the Bank Secrecy Act absent separate legislative action like the SAFER Banking Act.

What Happens If the Rule Stalls Past 2026

If the DEA doesn't finalize the rule by January 2027, the incoming administration could withdraw or modify the proposal. A new DEA administrator appointed after the 2026 transition could reopen the rulemaking or return marijuana to Schedule I, though such a reversal would require a new NPRM and scientific justification contradicting HHS's 2023 recommendation.

Legal scholars note that the CSA doesn't impose a statutory deadline for rescheduling rulemakings. The DEA has historically taken 18 to 36 months to finalize Schedule changes for other substances. The marijuana rescheduling, given its scale and political salience, is tracking toward the longer end of that range. For background on the procedural history and stakes of this rulemaking, see the CannIntel topic hub on DEA rescheduling.

Watch for this procedural signal: whether the DEA publishes a notice scheduling ALJ hearings before the end of Q3 2026. That would indicate the agency is on track for a final rule by year-end. Silence? Further delay.